Aspergillosis Treatment Market size is poised to cross USD 6 billion by the end of 2036, growing at a CAGR of 4% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of aspergillosis treatment was over 4 billion. The increasing incidence of aspergillosis infections, specifically among immunocompromised people, is primarily pushing the demand for innovative treatment techniques. Moreover, Aspergillosis can pose as a life-threatening disease so the requirement for effective treatment is rising continuously. All across the world, almost 3,000,000 cases of chronic pulmonary aspergillosis, around 223,100 cases of cryptococcal meningitis complexing HIV/AIDs, roughly 700,000 cases of intrusive candidiasis, approximately 500,000 cases of Pneumocystis jirovecii pneumonia, almost 250,000 cases of intrusive aspergillosis are reported, yearly.
The medical technology developments and drug modification will further help the aspergillosis treatment market to hike in its anticipated CAGR in the coming years. Improvements in medical technology and drug development have taken to more focused and efficient therapies, modifying patient results and treatment efficiency. Antifungal drugs are primarily utilized to cure Aspergillosis. Voriconazole, an antifungal drug is extensively employed because of its fewer side effects and more efficiency in comparison to other drugs. In the most substantial studies encircling treatment of aspergillosis, voriconazole demonstrated about 30% entire mortality on day 84, with reports of feedback rates ranging between 36% and 52.8%. The starting implementation of voriconazole was related to reduced length of hospital keeping in a sub-group assessment of the TRANSNET population. Itraconazole or Amphotericin B also cures the aspergillosis infection successfully.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
∼4% |
|
Base Year Market Size (2023) |
USD 4 Billion |
|
Forecast Year Market Size (2036) |
USD 6 Billion |
|
Regional Scope |
|
Type (Allergic, Chronic, Invasive Aspergillosis)
The allergic segment in the aspergillosis treatment market is anticipated to hold the largest share of over 50% in 2023. The allergic segment's revenue share in the market can be attributed to the developed incidences of respiratory problems like asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and pneumonia. In line with the National Center for Biotechnology Information, allergic bronchopulmonary aspergillosis (ABPA) impacts about 4 million people internationally. In developing countries, tuberculosis is the susceptible factor for over 90% of cases of allergic aspergillosis. Unequal to invasive aspergillosis, CPA emerges in non-immunocompromised patients, which debatably most ABPA patients are. The sickness of CPA is important involving weight loss, deeper fatigue, productive cough, major shortness of breath, and life-threatening hemoptysis.
Drug Class (Corticosteroids, Anti-fungal)
The antifungal segment is anticipated to hold around 60% share of the global aspergillosis treatment market by 2036. The dominance of antifungal drugs in the market can be accredited to their efficacy against infections and extensive implementation as a primary treatment choice. Healthcare providers' concentrate on developing modified and focused antifungal treatments is expected to maintain the segment's eminence, driving complete market growth. F2G, a key player in the aspergillosis treatment market, has accomplished a substantial milestone with the U.S. Food and Drug Administration's (FDA) approval of its New Drug Application (NDA) for Olorofim in December 2022, a revolutionary antifungal drug customized for invasive fungal infections, involving aspergillosis. This growth indicates a substantial development in antifungal treatments and presents promising aspects for patients combating life-threatening fungal infections in the market.
Our in-depth analysis of the global aspergillosis treatment market includes the following segments:
|
Type |
|
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channels |
|
North American Market Forecast
North America is expected to hold the largest share of the aspergillosis treatment market with almost 42% by 2036. North America will hold this position due to the reason that it has a high prevalence of situations that instigate the risk of aspergillosis, like lung diseases, HIV, and organ transplantation. This contributes to a wider patient pool needing HIV drug/medicine, and lung treatment. A calculated 7,199 deaths from fungal diseases happened in 2021 in North America. In North America, the most prevalent aspergillosis is the most clinically important section is Fumigati, comprising A. fumigatus, A. lentulus and A. udagawae among others.
European Market Analysis
Europe is set to hold the second-largest share in the aspergillosis treatment market in the coming timeline globally because of the European Government’s rigorous initiatives to combat aspergillosis and respiratory infections. Moreover, on 25th of October 2023, WHO/Europe and the European Centre for Disease Prevention and Control (ECDC) announced the weekly European Respiratory Virus Surveillance Summary (ERVISS) an online platform that shows integrated surveillance information for aspergillosis, influenza, COVID-19 and RSV in the WHO European Region, involving the European Union/European Economic Area.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?